SARS-CoV-2 variants from mink evade inhibition by antibodies

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies. These SARS-CoV-2 variants from mink were transmitted back to humans, raising concerns that minks could be a continuing source of infection of humans with SARS-CoV-2 variants with altered biological properties. Researchers at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, Germany, have now shown that an antibody used for COVID-19 therapy is unable to effectively inhibit SARS-CoV-2 harboring a spike mutation acquired in minks. In addition, the mutation reduced the inhibition of the virus by antibodies produced in SARS-CoV-2 infected humans. These results show that SARS-CoV-2 can acquire mutations in minks that may reduce control of the virus by the human immune system. The study and findings have been published in Cell Reports.

Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors

Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications

Viruses, Free Full-Text

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

Antibodies, Free Full-Text

Frontiers In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Viruses, Free Full-Text

Pathogens, Free Full-Text

Enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants BA.4 and BA.5

A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels